Advanced search in Research products
Research products
arrow_drop_down
Searching FieldsTerms
Any field
arrow_drop_down
includes
arrow_drop_down
Include:
The following results are related to COVID-19. Are you interested to view more results? Visit OpenAIRE - Explore.
1,577 Research products, page 1 of 158

  • COVID-19
  • Publications
  • CHEST Journal

10
arrow_drop_down
Date (most recent)
arrow_drop_down
  • Closed Access
    Authors: 
    S. Gysling; H. Morgan; O. Ifesemen; D. West; J. Conibear; N. Navani; E. O’Dowd; D. Baldwin; D. Humes; R. Hubbard;
    Publisher: Elsevier BV
  • Publication . Article . 2023
    Closed Access
    Authors: 
    Olusegun Olusanya; Cameron Baston;
    Publisher: Elsevier BV
  • Closed Access
    Authors: 
    Margaret B. Nolan; Matthew.E. Nolan; Thomas M. Piasecki; Michael C. Fiore;
    Publisher: Elsevier BV
  • Closed Access
    Authors: 
    Yoshiko Ishioka; Tomonori Makiguchi; Masamichi Itoga; Hisashi Tanaka; Kageaki Taima; Shintaro Goto; Sadatomo Tasaka;
    Publisher: Elsevier BV
  • Publication . Article . 2022
    Closed Access
    Authors: 
    Steven M. Hollenberg; David R. Janz; May Hua; Mark Malesker; Nida Qadir; Bram Rochwerg; Curtis N. Sessler; Geneva Tatem; Todd W. Rice; Todd W. Rice; +11 more
    Publisher: Elsevier BV
  • Closed Access
    Authors: 
    Ahmed Shebl, Ali; Daniya, Sheikh; Thomas R, Chandler; Stephen, Furmanek; Jiapeng, Huang; Julio A, Ramirez; Forest, Arnold; Rodrigo, Cavallazzi;
    Publisher: Elsevier BV

    Hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) community-acquired pneumonia (CAP) and associated comorbidities are at increased risk of cardiovascular complications. The magnitude of effect of cardiovascular complications and the role of prior comorbidities on clinical outcomes are not well defined.What is the impact of cardiovascular complications on mortality in hospitalized patients with SARS-CoV-2 CAP? What is the impact of co-morbidities and other risk factors on the risk of developing cardiovascular complications and mortality in these patients?This cohort study included 1,645 hospitalized patients with SARS-CoV-2 CAP. Cardiovascular complications were evaluated. The clinical course during hospitalization was described using a multistate model with 4 states: hospitalized with no cardiovascular complications, hospitalized with cardiovascular complications, discharged alive, and dead. Cox proportional hazards regression was used to analyze the impact of prior comorbid conditions on transitions between these states. Hazard ratios (HRs) and 95% confidence intervals (CIs) were reported.Cardiovascular complications occurred in 18% of patients hospitalized with SARS-CoV-2 CAP. The mortality rate in this group was 45% versus 13% in patients without cardiovascular complications. Males (HR: 1.32, 95% CI: 1.03-1.68), older adults (HR: 1.34, 95% CI: 1.03-1.75), patients with congestive heart failure (HR: 1.59, 95% CI: 1.18-2.15), coronary artery disease (HR: 1.34, 95% CI: 1.00-1.79), atrial fibrillation (HR: 1.43, 95% CI: 1.06-1.95), direct admissions to the ICU (HR: 1.77, 95% CI: 1.36-2.32) and PaO

  • Closed Access
    Authors: 
    Wesley H. Self; Allison P. Wheeler; Thomas G. Stewart; Harry Schrager; Jason Mallada; Christopher B. Thomas; Vince D. Cataldo; Hollis R. O’Neal; Nathan I. Shapiro; Conor Higgins; +41 more
    Publisher: Elsevier BV
  • Closed Access
    Authors: 
    Nunzia Decembrino; Eloisa Gitto; Tiziana Fedeli; Ferdinando Spagnuolo; Luigi Orfeo; Corrado Moretti; Paola Cogo; Nicola Pozzi;
  • Closed Access
    Authors: 
    Arturo Casadevall; Jeffrey P. Henderson;
    Publisher: Elsevier BV
  • Closed Access
    Authors: 
    ANANT JAIN; IAN KAPLAN; TARIK AL-BERMANI; ALINA KIFAYAT; LISA P PAUL;
    Publisher: Elsevier BV
Advanced search in Research products
Research products
arrow_drop_down
Searching FieldsTerms
Any field
arrow_drop_down
includes
arrow_drop_down
Include:
The following results are related to COVID-19. Are you interested to view more results? Visit OpenAIRE - Explore.
1,577 Research products, page 1 of 158
  • Closed Access
    Authors: 
    S. Gysling; H. Morgan; O. Ifesemen; D. West; J. Conibear; N. Navani; E. O’Dowd; D. Baldwin; D. Humes; R. Hubbard;
    Publisher: Elsevier BV
  • Publication . Article . 2023
    Closed Access
    Authors: 
    Olusegun Olusanya; Cameron Baston;
    Publisher: Elsevier BV
  • Closed Access
    Authors: 
    Margaret B. Nolan; Matthew.E. Nolan; Thomas M. Piasecki; Michael C. Fiore;
    Publisher: Elsevier BV
  • Closed Access
    Authors: 
    Yoshiko Ishioka; Tomonori Makiguchi; Masamichi Itoga; Hisashi Tanaka; Kageaki Taima; Shintaro Goto; Sadatomo Tasaka;
    Publisher: Elsevier BV
  • Publication . Article . 2022
    Closed Access
    Authors: 
    Steven M. Hollenberg; David R. Janz; May Hua; Mark Malesker; Nida Qadir; Bram Rochwerg; Curtis N. Sessler; Geneva Tatem; Todd W. Rice; Todd W. Rice; +11 more
    Publisher: Elsevier BV
  • Closed Access
    Authors: 
    Ahmed Shebl, Ali; Daniya, Sheikh; Thomas R, Chandler; Stephen, Furmanek; Jiapeng, Huang; Julio A, Ramirez; Forest, Arnold; Rodrigo, Cavallazzi;
    Publisher: Elsevier BV

    Hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) community-acquired pneumonia (CAP) and associated comorbidities are at increased risk of cardiovascular complications. The magnitude of effect of cardiovascular complications and the role of prior comorbidities on clinical outcomes are not well defined.What is the impact of cardiovascular complications on mortality in hospitalized patients with SARS-CoV-2 CAP? What is the impact of co-morbidities and other risk factors on the risk of developing cardiovascular complications and mortality in these patients?This cohort study included 1,645 hospitalized patients with SARS-CoV-2 CAP. Cardiovascular complications were evaluated. The clinical course during hospitalization was described using a multistate model with 4 states: hospitalized with no cardiovascular complications, hospitalized with cardiovascular complications, discharged alive, and dead. Cox proportional hazards regression was used to analyze the impact of prior comorbid conditions on transitions between these states. Hazard ratios (HRs) and 95% confidence intervals (CIs) were reported.Cardiovascular complications occurred in 18% of patients hospitalized with SARS-CoV-2 CAP. The mortality rate in this group was 45% versus 13% in patients without cardiovascular complications. Males (HR: 1.32, 95% CI: 1.03-1.68), older adults (HR: 1.34, 95% CI: 1.03-1.75), patients with congestive heart failure (HR: 1.59, 95% CI: 1.18-2.15), coronary artery disease (HR: 1.34, 95% CI: 1.00-1.79), atrial fibrillation (HR: 1.43, 95% CI: 1.06-1.95), direct admissions to the ICU (HR: 1.77, 95% CI: 1.36-2.32) and PaO

  • Closed Access
    Authors: 
    Wesley H. Self; Allison P. Wheeler; Thomas G. Stewart; Harry Schrager; Jason Mallada; Christopher B. Thomas; Vince D. Cataldo; Hollis R. O’Neal; Nathan I. Shapiro; Conor Higgins; +41 more
    Publisher: Elsevier BV
  • Closed Access
    Authors: 
    Nunzia Decembrino; Eloisa Gitto; Tiziana Fedeli; Ferdinando Spagnuolo; Luigi Orfeo; Corrado Moretti; Paola Cogo; Nicola Pozzi;
  • Closed Access
    Authors: 
    Arturo Casadevall; Jeffrey P. Henderson;
    Publisher: Elsevier BV
  • Closed Access
    Authors: 
    ANANT JAIN; IAN KAPLAN; TARIK AL-BERMANI; ALINA KIFAYAT; LISA P PAUL;
    Publisher: Elsevier BV